Agilent Technologies, Inc. logo

Agilent Technologies, Inc.

A

NYSEHealthcareMedical - Diagnostics & Research

Regular session

$152.93

−$6.07 · -3.82%

Aug 24, 2:00 PM ET

A company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

86

Deep Value

Momentum

48

Neutral

Sentiment

61

Bullish

Risk resilience

51

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Padraig McDonnell
Listed since
Nov 18, 1999
Employees
18,000

Market position

Day range

Current $152.93

52-week range

Current $152.93

Open
$156.56
Previous close
$159
Volume
1.61M
0.72× average
Average volume
2.24M
Average daily volume
Market cap
43.19B USD
Beta
1.23
Market reference 1
50-day average
$137.52
+11.21% above average
200-day average
$131.3
+16.47% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
42.98B USD
EV / EBITDA
23.43×
Earnings yield
3.15%
Free cash flow yield
2.78%

Profitability & efficiency

Return on equity
19.33%
Return on assets
10.24%
Return on invested capital
12.57%

Financial health

Current ratio
1.96×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%43%29%15%Gross margin, FY2021: 53.92%Gross margin, FY2022: 54.35%Gross margin, FY2023: 50.71%Gross margin, FY2024: 54.30%Gross margin, FY2025: 52.43%Operating margin, FY2021: 21.32%Operating margin, FY2022: 23.63%Operating margin, FY2023: 19.76%Operating margin, FY2024: 22.86%Operating margin, FY2025: 21.29%Net margin, FY2021: 19.15%Net margin, FY2022: 18.31%Net margin, FY2023: 18.15%Net margin, FY2024: 19.80%Net margin, FY2025: 18.75%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 53.92%. Gross margin FY2022 54.35%. Gross margin FY2023 50.71%. Gross margin FY2024 54.30%. Gross margin FY2025 52.43%. Operating margin FY2021 21.32%. Operating margin FY2022 23.63%. Operating margin FY2023 19.76%. Operating margin FY2024 22.86%. Operating margin FY2025 21.29%. Net margin FY2021 19.15%. Net margin FY2022 18.31%. Net margin FY2023 18.15%. Net margin FY2024 19.80%. Net margin FY2025 18.75%.

Income trends

Revenue

6.95B USD+6.73%

Operating income

1.48B USD-0.60%

Net income

1.3B USD+1.09%
Income trends across reported periods7.52B USD5.23B USD2.93B USD636.2M USDRevenue, FY2021: 6.32B USDRevenue, FY2022: 6.85B USDRevenue, FY2023: 6.83B USDRevenue, FY2024: 6.51B USDRevenue, FY2025: 6.95B USDOperating income, FY2021: 1.35B USDOperating income, FY2022: 1.62B USDOperating income, FY2023: 1.35B USDOperating income, FY2024: 1.49B USDOperating income, FY2025: 1.48B USDNet income, FY2021: 1.21B USDNet income, FY2022: 1.25B USDNet income, FY2023: 1.24B USDNet income, FY2024: 1.29B USDNet income, FY2025: 1.3B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.32B USD. Revenue FY2022 6.85B USD. Revenue FY2023 6.83B USD. Revenue FY2024 6.51B USD. Revenue FY2025 6.95B USD. Operating income FY2021 1.35B USD. Operating income FY2022 1.62B USD. Operating income FY2023 1.35B USD. Operating income FY2024 1.49B USD. Operating income FY2025 1.48B USD. Net income FY2021 1.21B USD. Net income FY2022 1.25B USD. Net income FY2023 1.24B USD. Net income FY2024 1.29B USD. Net income FY2025 1.3B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.95B USD6.51B USD6.83B USD6.85B USD6.32B USD
Cost of goods sold3.31B USD2.98B USD3.37B USD3.13B USD2.91B USD
Gross profit3.64B USD3.54B USD3.47B USD3.72B USD3.41B USD
Research and development455M USD479M USD481M USD467M USD441M USD
Selling, general, and administrative1.71B USD1.52B USD1.63B USD1.64B USD1.62B USD
Operating expenses2.16B USD2.05B USD2.12B USD2.1B USD2.06B USD
Interest income62M USD80M USD51M USD9M USD2M USD
Interest expense112M USD96M USD95M USD84M USD81M USD
Depreciation and amortization288M USD257M USD271M USD317M USD321M USD
Operating income1.48B USD1.49B USD1.35B USD1.62B USD1.35B USD
Net income1.3B USD1.29B USD1.24B USD1.25B USD1.21B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+2.83%
11 comparable reports
Latest EPS result
1.49
Estimate 1.41 · Beat by 5.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.651.51.351.2Q4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 25, 2024: actual 1.46, estimate 1.41, surprise +3.55%, Beat. Q1 2025, reported Feb 26, 2025: actual 1.31, estimate 1.28, surprise +2.34%, Beat. Q2 2025, reported May 28, 2025: actual 1.31, estimate 1.26, surprise +3.97%, Beat. Q3 2025, reported Aug 27, 2025: actual 1.37, estimate 1.37, surprise 0.00%, Met estimate. Q4 2025, reported Nov 24, 2025: actual 1.59, estimate 1.58, surprise +0.36%, Beat. Q1 2026, reported Feb 25, 2026: actual 1.36, estimate 1.37, surprise -0.73%, Miss. Q2 2026, reported May 27, 2026: actual 1.49, estimate 1.41, surprise +5.67%, Beat. Q3 2026, reported Aug 26, 2026: actual —, estimate 1.49, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.92B1.79B1.67B1.55BQ4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 25, 2024: actual 1.7B USD, estimate 1.67B USD, surprise +1.70%, Beat. Q1 2025, reported Feb 26, 2025: actual 1.68B USD, estimate 1.67B USD, surprise +0.66%, Beat. Q2 2025, reported May 28, 2025: actual 1.67B USD, estimate 1.63B USD, surprise +2.54%, Beat. Q3 2025, reported Aug 27, 2025: actual 1.74B USD, estimate 1.68B USD, surprise +3.17%, Beat. Q4 2025, reported Nov 24, 2025: actual 1.84B USD, estimate 1.83B USD, surprise +0.36%, Beat. Q1 2026, reported Feb 25, 2026: actual 1.8B USD, estimate 1.81B USD, surprise -0.54%, Miss. Q2 2026, reported May 27, 2026: actual 1.84B USD, estimate 1.8B USD, surprise +2.03%, Beat. Q3 2026, reported Aug 26, 2026: actual —, estimate 1.84B USD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.956

2024 complete year+42.3% since 2019

2026 partial: $0.765

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 30, 2026

$0.255

Quarterly

Record Jun 30, 2026 · Payment Jul 22, 2026

Dividend

Ex-dividend Mar 31, 2026

$0.255

Irregular

Record Mar 31, 2026 · Payment Apr 22, 2026

Dividend

Ex-dividend Jan 6, 2026

$0.255

Quarterly

Record Jan 6, 2026 · Payment Jan 28, 2026

Dividend

Ex-dividend Sep 30, 2025

$0.248

Quarterly

Record Sep 30, 2025 · Payment Oct 22, 2025

Dividend

Ex-dividend Jul 1, 2025

$0.248

Quarterly

Record Jul 1, 2025 · Payment Jul 23, 2025

Dividend

Ex-dividend Apr 1, 2025

$0.248

Quarterly

Record Apr 1, 2025 · Payment Apr 23, 2025

ETFs holding A

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research A

research.disclaimer